Radioiodinated Persistent Luminescence Nanoplatform for Radiation‐Induced Photodynamic Therapy and Radiotherapy

Wang, Qiang; Liu, Nian; Hou, Zhenyu; Shi, Junpeng; X, Su; Sun, Xiaolian

doi:10.1002/adhm.202000802

Cited by 43 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the excellent tumor homologous adhesion and combined therapy effect, the colorectal tumors were obtained good inhibition. Sun et al developed 131 I labeled ZnPc(COOH) 4 conjugated ZnGa 2 O 4 :Cr 3+ nanoplatform ( 131 I-ZGCs-ZnPcC4) for both radiation-induced PDT and radionuclide therapy (RT) [ 131 ]. 131 I as the therapeutic radionuclides not only produced the gamma-ray for RT but also served as internal excitation source to activate ZnGa 2 O 4 :Cr 3+ with long-lasting luminescence for further continuously generating PDT from ZnPc(COOH) 4 .…”

Section: Plnps Based Cancer Therapymentioning

confidence: 99%

Persistent luminescence nanoparticles for cancer theranostics application

et al. 2021

Self Cite

View full text Add to dashboard Cite

Persistent luminescence nanoparticles (PLNPs) are unique optical materials that emit afterglow luminescence after ceasing excitation. They exhibit unexpected advantages for in vivo optical imaging of tumors, such as autofluorescence-free, high sensitivity, high penetration depth, and multiple excitation sources (UV light, LED, NIR laser, X-ray, and radiopharmaceuticals). Besides, by incorporating other functional molecules, such as photosensitizers, photothermal agents, or therapeutic drugs, PLNPs are also widely used in persistent luminescence (PersL) imaging-guided tumor therapy. In this review, we first summarize the recent developments in the synthesis and surface functionalization of PLNPs, as well as their toxicity studies. We then discuss the in vivo PersL imaging and multimodal imaging from different excitation sources. Furthermore, we highlight PLNPs-based cancer theranostics applications, such as fluorescence-guided surgery, photothermal therapy, photodynamic therapy, drug/gene delivery and combined therapy. Finally, future prospects and challenges of PLNPs in the research of translational medicine are also discussed.

show abstract

Section: Plnps Based Cancer Therapymentioning

confidence: 99%

Persistent luminescence nanoparticles for cancer theranostics application

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In particular the survival curve was significantly prolonged and, at the same time, histopathology on different organs found no strong side effects. The use of 131 I as both radiotherapy and PDT Cerenkov light source was also investigated by [31] using a Zn based nanoplatform. Both in vitro and in vivo experiments were carried out using 4T1 cell line.…”

Section: Pdt Using Isotopes Emitting Cerenkov Radiationmentioning

confidence: 99%

Photodynamic Therapy Using Cerenkov and Radioluminescence Light

Spinelli

Boschi

2021

Front. Phys.

View full text Add to dashboard Cite

In this short review the potential use of Cerenkov radiation and radioluminescence as internal sources for Photodynamic therapy (PDT) is discussed. PDT has been developed over the course of more than 100 years and is based on the induced photo conversion of a drug called photosensitizer (PS) that triggers the production of cytotoxic reactive oxygen species (ROS) leading to the killing of the cells. In order to overcome the problem of light penetration in the tissues, different solutions were proposed in the past. The use of radioisotopes like: 18F, 64Cu, 90Y, 177Lu as internal light sources increase the light fluence at the PS compared to an external source, resulting in a larger cytotoxic effect.

show abstract

“…Upon decay of 131 I, a radionuclide used in radiotherapy, Cerenkov luminescence is generated and absorbed by the PLNP that produces PeL and excite the PS generating 1 O 2 . Thus, yielding a system capable of treating diseases using combined radiotherapy and PDT [ 289 ]. No leakage of 131 I and ZnPcC4 was observed in aqueous solution for over 7 days, which confirmed the stability of the 131 I–ZnGa 2 O 4 :Cr III –ZnPcC4 system [ 289 ].…”

Section: Persistent Luminescence In Luminescence Imaging Of Biologmentioning

confidence: 99%

“…Thus, yielding a system capable of treating diseases using combined radiotherapy and PDT [ 289 ]. No leakage of 131 I and ZnPcC4 was observed in aqueous solution for over 7 days, which confirmed the stability of the 131 I–ZnGa 2 O 4 :Cr III –ZnPcC4 system [ 289 ]. Extensive photocytotoxicity in vivo and in vitro against 4T1 cells was observed, in the absence of external light stimulation, for the ZnGa 2 O 4 :Cr III –ZnPcC4 system when compared with ZnPcC4, Na 131 I, or Na 131 I+ZnPcC4 ( Figure 21 ).…”

Section: Persistent Luminescence In Luminescence Imaging Of Biologmentioning

confidence: 99%

See 1 more Smart Citation

Opportunities for Persistent Luminescent Nanoparticles in Luminescence Imaging of Biological Systems and Photodynamic Therapy

et al. 2020

View full text Add to dashboard Cite

The use of luminescence in biological systems allows us to diagnose diseases and understand cellular processes. Persistent luminescent materials have emerged as an attractive system for application in luminescence imaging of biological systems; the afterglow emission grants background-free luminescence imaging, there is no need for continuous excitation to avoid tissue and cell damage due to the continuous light exposure, and they also circumvent the depth penetration issue caused by excitation in the UV-Vis. This review aims to provide a background in luminescence imaging of biological systems, persistent luminescence, and synthetic methods for obtaining persistent luminescent materials, and discuss selected examples of recent literature on the applications of persistent luminescent materials in luminescence imaging of biological systems and photodynamic therapy. Finally, the challenges and future directions, pointing to the development of compounds capable of executing multiple functions and light in regions where tissues and cells have low absorption, will be discussed.

show abstract

Radioiodinated Persistent Luminescence Nanoplatform for Radiation‐Induced Photodynamic Therapy and Radiotherapy

Cited by 43 publications

References 22 publications

Persistent luminescence nanoparticles for cancer theranostics application

Persistent luminescence nanoparticles for cancer theranostics application

Photodynamic Therapy Using Cerenkov and Radioluminescence Light

Opportunities for Persistent Luminescent Nanoparticles in Luminescence Imaging of Biological Systems and Photodynamic Therapy

Contact Info

Product

Resources

About